FMR CORP 13D and 13G filings for Enliven Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-09 09:03 am Purchase |
2024-02-08 | 13G | Enliven Therapeutics, Inc. ELVN |
FMR CORP | 5,902,265 14.321% |
1,482,684 (+33.55%) |
Filing |
| 2023-05-10 09:45 am Purchase |
2023-05-09 | 13G | Enliven Therapeutics, Inc. ELVN |
FMR CORP | 4,419,581 10.749% |
4,419,581 (New Position) |
Filing |